Xiaomo Biotech is an expert on RNA biosynthesis. Our green biomanufacturing technology produces highly potent, specific, and cost-effective siRNAs (to kilograms) for various RNAi applications including gene knockdown in mammalian cells, high-throughput RNAi screen and RNAi pesticide. Xiaomo is committed to developing cutting-edge biotech products based on RNA interference (RNAi), a natural process which uses small interfering RNAs (siRNAs) to silence target genes in a precise manner. Xiaomo possesses a revolutionary RNAi platform technology known as the ‘prokaryotic siRNA’ (pro-siRNA) technology. The pro-siRNA technology uses bacteria as siRNA ‘factory’ instead of using chemical synthesis. This unique biomanufacturing method enables cost-effective and environmentally friendly production of highly effective siRNAs on a massive scale. Xiaomo has the capacity to produce siRNAs in gram to kilogram scales using bacterial fermentation. Xiaomo has also developed a customized high-throughput RNAi screen technique to identify potential therapeutic target genes in a disease, that could lead to the development of novel RNAi therapeutics. Currently, Xiaomo is offering various biomanufactured siRNA and RNAi library products to the R&D market. Xiaomo’s R&D efforts focus on developing first-in-class RNA pesticides for important crop pests including fungi, insects and nematodes. The ultimate goal of Xiaomo is to provide effective and affordable RNAi solutions for improving both human health and agricultural health. Xiaomo Biotech (www.xiaomobio.com) was founded at Hong Kong Science Park in 2019. We have recently established R&D and production sites in Shanghai Zhangjiang and Suzhou Kunshan China.
Viruj Group
Viruj Group was established in 2014 by a group of young & experienced professionals with the specific objective to develop & produce complex, small to large volume, technology driven Intermediates/ API at competitive prices, thus providing the critical India advantage for a CRO/ NCE Molecules across the world. We are a partner for various Innovator companies to supply High Quality API’s /Intermediates & Fine chemicals at competitive prices Complying with Regulatory Requirements. Our Experienced R&D team – well qualified & equipped to develop most complex Intermediates/ APIs and expertise to handle wide range of chemical reactions. Manufacturing capabilities ranging from gram level to multiple ton lots. Strong Intellectual Property Management and Regulatory back up & Absolute assurance of best quality APIs. Expertise in the development of novel, non-infringing and cost-effective API’s Speed to market for customers and support the NCE / Dossier by time bound development. Timely delivery and prompt response to all queries of the customers CRO/CDMO – We intend to take up any projects in this area working closely with you team for small or big enquiries, we have a dedicated team working in this area. Flow Chemistry – Our process lab is established with a motto to make API / Intermediates and Fine Chemicals in Flow chemistry mode as far as the molecule permits, we have established few global business and making R&D/ Pilot scale modules and converting existing batch chemistry to flow chemistry way. We are ready to take up projects for any commercial scale products on Pharma/ Agro/Fine Chemicals space.
Vipragen Biosciences Private Limited
Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. Additionally, the laboratory has been certified by AAALAC, NABL, and DCGI to support discovery research. Vipragen has deep scientific and research knowledge with a combined experience of over 150 years of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen Biosciences Pvt. Ltd. is a globally recognized Contract Research Organization(CRO) which has been in the industry for more than a decade now and specializing in delivering comprehensive pre-clinical services to Global Drug Discovery companies. We are OECD-GLP certified and AAALAC accredited laboratory with the State-of-the-art Vivarium to carry out safety studies for regulatory submissions. Vipragen has deep scientific and research knowledge of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen, a renowned Contract Research Organization (CRO), offers comprehensive services for global Pharmaceutical, Biopharmaceutical, Chemical, Nutraceutical and Medical Device companies. With over 12 years of experience, Vipragen Biosciences Private Limited is dedicated to delivering quality services. Under the leadership of Dr. Chandrashekaran Siddamadappa, Chairman and Managing Director, Vipragen has emerged as an Integrated Pre-clinical CRO, championing sustainability, integrity, safety and quality. Our state-of-the-art Vivarium holds Global certifications like OECD GLP, AAALAC and NABL, supported by multidisciplinary experts and equipped with 21CFR Part 11 compliance systems and processes. We ensure reliable data adhering to global standards with a focus on customer satisfaction. Our diverse portfolio includes Analytical, Toxicology and Chemistry services tailored to meet stringent regulatory submission requirements across the industries, ensuring compliance and transparency for clients across the industry spectrum.
Vettiva Saúde Animal
Vettiva Animal Health is a biotech startup focused exclusively on Research and Development (R&D) and commercialization of innovative pharmaceuticals derived from Medical Cannabis. It is also the first company to formalizeclinical development of cannabidiol-based veterinary candidate therapies with the Brazilian Ministry of Agriculture, Livestock, and Supply (MAPA).
UNESP
Sao Paulo State University and V-BioPharma, a brazilian CDMO
UI Pharmaceuticals
Contract pharmaceutical services include: Pre-formulation studies Formulation development (including lyophilization cycle development) Clinical supply manufacturing and testing Small scale commercial manufacturing and testing Analytical method development and validation Routine quality control analysis Stability studies Active pharmaceutical ingredient (API) and excipient release testing UI Pharmaceuticals is able to manufacture most dosage forms including sterile solutions and lyophilized powders; tablets; capsules; and non-sterile semisolids and liquids. | UI Pharmaceuticals stands as the longest-running, FDA-registered, university-affiliated pharmaceutical manufacturing facility in the United States. Since 1974, we have been a reliable partner in pharmaceutical product development, manufacturing, and testing, with services covering sterile solutions, lyophilized products, tablets, capsules, and non-sterile formats, including powders, semisolids, and liquids. Our experienced team brings deep industry knowledge and a commitment to the highest standards of quality, ensuring full compliance with cGMP regulations. With a steadfast dedication to client satisfaction, UI Pharmaceuticals supports innovation and excellence in contract pharmaceutical manufacturing and testing.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.
Transpharm Preclinical Solutions
TransPharm is an AAALAC accredited facility, “#001301” and registered with the Office of Laboratory Animal Welfare (OLAW), Assurance #A4747-01. Our only focus is Infectious Disease research, and I believe no one can compete with us regarding passion for this research or match our competitive rate. The company is housed in an interconnected 8,300-sq. ft. complex of buildings including a 3,100-sq. ft. vivarium with an attending 230 sq. ft. surgical suite. The vivarium is split with negative and positive pressured areas equipped with bioBubble® clean rooms. The facility is designed to handle all BSL II Applications. General laboratory work is conducted in a 1,700-sq. ft. wet lab equipped to handle all microbiological procedures and analyses. This work area includes biological containment hoods, sterile workstations, chemical use hoods, and general lab work benches. The entire facility is backed up by a 90,000-watt generator to avoid any catastrophic loss of data. The administrative area includes 1,220 sq. ft. of office space complete with video-link conference room. Our lab is spearheaded by Marci Peek, acting as the Chief Scientific Officer. We have a staff of 6 employees, with most of them being AALAS certified and one being a Board-Certified Veterinary Technician.
TheraFluor
TheraFluor, Inc. Overview TheraFluor, Inc. is a privately held theranostic company pioneering the targeted use of innovative nanomedicines to improve health outcomes for cancer patients. The company is developing a cutting-edge technology platform for cancer detection, fluorescence-guided surgery (FGS), and phototherapy (PT), designed to maximize patient benefits while minimizing side effects. Headquartered in Portland, Oregon, TheraFluor was founded on intellectual property from Oregon State University and is working to bring its proprietary nanoparticle technology and specialized instruments to both human and veterinary medicine markets. For more information, visit www.therafluor.com. Innovative Solutions for Cancer Treatment TheraFluor’s novel approach transforms the way surgeons detect, remove, and treat cancer. Our technology enables surgeons to more effectively distinguish between healthy and malignant cells in solid tumors during fluorescence-guided surgery (FGS), leading to cleaner margins and lower recurrence rates. At the heart of this technology is our patented tumor-activatable near-infrared (NIR) nanoparticle (SiNc-NP), which becomes fluorescent when it accumulates in solid tumors. SiNc-NP is an innovative, dual-function nanomedicine that combines fluorescent-imaging and phototherapeutic capabilities with both photodynamic therapy (PDT) and photothermal therapy (PTT) properties, enabling it to both guide tumor removal and kill residual cancer cells post-surgery. Encapsulated in biodegradable nanoparticles, this smart nanomedicine is activated in tumors and offers significant advantages over current FDA-approved fluorescent agents. SiNc-NP is non-toxic with enhanced fluorescent and photostable properties, enabling more precise surgery and tumor resection. Additionally, TheraFluor’s proprietary NIR camera system delivers high-quality visualization of both healthy and malignant tissue, making FGS technology accessible to every surgeon. Our software, powered by real-time images from the NIR camera, assists surgeons in achieving complete tumor resection. A Strong Business Model: Veterinary and Human Medicine Our strategy involves pursuing a dual-market approach. We are initially focusing on the veterinary market, where regulatory hurdles are lower and the path to revenue is faster. In parallel, we are looking for a strategic partner or to license our technology for use in human medicine to a commercial partner, advancing these products toward human clinical applications. This parallel approach will provide synergistic benefits for both regulatory paths. Veterinary Applications: Targeting Companion Animal Cancer TheraFluor is committed to improving the way veterinarians detect and treat cancer in dogs and cats. Cancer rates in pets, especially dogs, are high—often higher than in humans. Surgery is the primary treatment for most solid tumors, but challenges remain in achieving clean margins during surgical resection. A major unmet need exists in veterinary oncology, particularly for addressing tumors such as mast cell tumors (MCTs), which are the most common malignant tumors in dogs. MCTs are difficult to remove completely, with recurrence rates of 30% to 64% if clean margins aren’t achieved. The need for repeat surgeries or follow-up chemotherapy and radiation therapy drives up costs for pet owners and can lead to shortened lifespans for pets. Initial studies have demonstrated the optimal dosage of SiNc-NP for targeting MCTs in both mouse models and canines. SiNc-NP was found safe for use in dogs over an ~30-fold dose range with no adverse events. Furthermore, SiNc-NP helped the surgical veterinarian identify additional MCTs (~25%) that were not known prior to SiNc-NP administration. Path to Regulatory Approval and Future Growth TheraFluor is focusing on gaining approval from the Center for Veterinary Medicine for our SiNc-NP product. This regulatory process is expected to take 3-5 years and will cost between $3-5 million. Instrument development and scaling for market will require an additional $2-3 million. TheraFluor’s long-term vision includes expanding into human medicine through strategic partnerships/licensing and leveraging our proven technology to make a significant impact on both veterinary and human oncology markets. Market Opportunity in Human Oncology: Ensuring Clean Margins in Tumor Resection The challenge of achieving clean margins during tumor resection is a significant issue in human oncology as well. For many solid tumors, the success of surgery depends on completely removing the cancerous tissue, with any remaining cancer cells leading to recurrence and potentially fatal outcomes. Despite advancements in imaging techniques, surgeons often struggle to clearly distinguish between healthy and malignant tissue, especially in complex or deeply embedded tumors. TheraFluor’s innovative technology offers a promising solution by providing real-time fluorescence-guided visualization, enabling surgeons to more accurately identify tumor boundaries and improve surgical precision. Additionally, the SiNc-NP’s phototherapeutic properties will enable surgeons to eliminate residual cancer cells in the surgical bed significantly reducing recurrence rates and the need for follow-up treatments, such as additional surgeries or radiation therapy, ultimately improving patient survival and quality of life. The market for surgical aids aimed at improving tumor margin delineation is substantial, with growing demand for advanced technologies in cancer surgery. As the global incidence of cancer continues to rise, particularly in complex cancers like gliomas, breast cancer, and sarcomas, the potential for TheraFluor’s platform in human oncology is vast, offering a major opportunity to enhance surgical outcomes and lower overall healthcare costs. Near-Infrared Imaging Systems for Surgical Guidance Near-infrared (NIR) imaging systems are emerging as powerful tools in the field of surgical guidance, providing real-time, high-resolution visualization of tissues during surgery. These systems utilize NIR fluorescence to highlight specific tissues or tumors, enabling surgeons to differentiate between healthy and malignant cells with greater accuracy than traditional imaging techniques. NIR imaging offers several advantages, including deep tissue penetration, minimal tissue damage, and the ability to visualize tumors that are otherwise difficult to detect with the naked eye. By incorporating NIR fluorescent agents, such as those developed by TheraFluor, these systems can enhance the precision of tumor resections, ensuring that cancerous tissues are completely removed while preserving surrounding healthy tissues. As a result, NIR imaging is increasingly being adopted in cancer surgeries, offering the potential to reduce recurrence rates, improve surgical outcomes, and shorten recovery times. With the growing adoption of minimally invasive surgery and a shift towards precision medicine, the market for NIR imaging systems is expected to expand rapidly, representing a significant opportunity for companies like TheraFluor that are innovating in this space. Team and Funding TheraFluor has assembled a talented team with deep expertise in biotechnology, fluorescent chemistry, regulatory affairs, and market strategy. We have also assembled a strong advisory network, including key inventors, veterinary experts, and collaborators at Oregon State University. TheraFluor has received significant funding from Oregon Nanoscience and Microtechnologies Institute (ONAMI) and two SBIR Phase 1 grants. We are applying for additional non-dilutive funding through SBIR Phase 2 programs to advance dye and instrument development. We are actively raising a seed round from angel investors that will be followed by a larger Series A round in two years. Licensing Opportunity: A Strategic Advantage for Partners TheraFluor’s proprietary near-infrared (NIR) imaging and therapeutic platform offers a unique and highly differentiated solution in the rapidly evolving oncology space, making it an attractive licensing opportunity for companies looking to advance cancer treatment technologies. With its dual functionality—providing both real-time tumor visualization and therapeutic capabilities—our technology has the potential to significantly enhance surgical outcomes, reduce recurrence rates, and improve patient survival across both veterinary and human medicine. By licensing this cutting-edge technology, companies can quickly enter the lucrative human oncology market with a proven, patent-protected solution, bypassing the long and costly development cycles typically associated with new medical technologies. Moreover, as the global oncology market continues to grow, particularly in minimally invasive and precision surgeries, this technology offers a strategic advantage for partners seeking to differentiate themselves in a competitive landscape. TheraFluor is actively seeking commercial partners to license its technology, providing them with a high-impact, innovative tool that can transform cancer treatment and position them at the forefront of the next generation of medical advancements.